Jiangxi Xianhe Medical Technology

Jiangxi Xianhe Medical Technology is a clinical-stage biotechnology company and a subsidiary of Regend Therapeutics, specializing in the development of regenerative cell therapies for chronic and irreversible organ diseases. The company's core technology platform focuses on tissue-specific progenitor cells, notably P63+ lung basal stem cells, to repair and regenerate damaged organ structures. Its lead candidate, REGEND001 (Aeriotemcel), is an autologous cell therapy currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), where it has shown potential to restore lung function and alveolar integrity. Beyond respiratory indications, the company is expanding its pipeline into nephrology and vascular diseases, leveraging proprietary isolation and expansion techniques for adult stem cells.